GAO: FDA fails to track drugmakers conducting postmarket studies
The Government Accountability Office released a report showing the FDA has been unable to track the progress of many of the postmarket studies it required from drugmakers between 1992 and 2008. Dr. Joshua Sharfstein, deputy FDA commissioner, said that since 2007 the FDA has "completely overhauled" its postmarket surveillance processes, and it continues to work to fix past problems.
Washington Post, The | 10/26
This story published in FDLI SmartBrief on 10/28/2009
More from SmartBrief:
Immucor submits 30-day working response to FDA
Tuesday, August 11, 2009
FDA investigates safety of alcoholic energy drinks
Tuesday, November 17, 2009
Trade group urges FDA safety seal for Web drug, device data
Tuesday, November 10, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|